Cardinal Health Beheer
Beheer criteriumcontroles 2/4
De CEO Cardinal Health is Jason Hollar, benoemd in Sep2022, heeft een ambtstermijn van 2.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 25.65M, bestaande uit 5.6% salaris en 94.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.008% van de aandelen van het bedrijf, ter waarde $ 2.16M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.2 jaar en 4.3 jaar.
Belangrijke informatie
Jason Hollar
Algemeen directeur
US$25.7m
Totale compensatie
| Percentage CEO-salaris | 5.6% |
| Dienstverband CEO | 2.2yrs |
| Eigendom CEO | 0.008% |
| Management gemiddelde ambtstermijn | 2.2yrs |
| Gemiddelde ambtstermijn bestuur | 4.3yrs |
Recente managementupdates
Recent updates
Cardinal Health (NYSE:CAH) Has Affirmed Its Dividend Of $0.5056
Nov 09
Results: Cardinal Health, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Nov 05Cardinal Health Q1 Earnings: Margins Signal More Upside
Nov 04Cardinal Health (NYSE:CAH) Will Pay A Dividend Of $0.5056
Sep 24Here's Why We Think Cardinal Health (NYSE:CAH) Is Well Worth Watching
Sep 17Cardinal Health (NYSE:CAH) Is Due To Pay A Dividend Of $0.5056
Aug 19Cardinal Health: Growth Headwinds Ahead
Aug 01Cardinal Health: Growing Into The Valuation
Jul 02Cardinal Health (NYSE:CAH) Has Announced That It Will Be Increasing Its Dividend To $0.5056
Jun 11Cardinal Health's Valuation Makes The Name Unattractive
May 26Cardinal Health Q3 Earnings: Undervalued On Strong Guidance
May 03Potential Upside For Cardinal Health, Inc. (NYSE:CAH) Not Without Risk
Apr 14Is Cardinal Health, Inc. (NYSE:CAH) Trading At A 50% Discount?
Mar 09Cardinal Health: Continued Business Growth And Huge Medical Supplies Market Penetration
Feb 20Cardinal Health, Inc. (NYSE:CAH) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Feb 03Investors Aren't Entirely Convinced By Cardinal Health, Inc.'s (NYSE:CAH) Revenues
Dec 28Cardinal Health Is Setting Up For A Great 2024
Dec 21Cardinal Health, Inc. (NYSE:CAH) Shares Could Be 45% Below Their Intrinsic Value Estimate
Nov 03Cardinal Health: A Revenue Growth Gem Plagued By Symptoms Of Negative Equity
Oct 13Cardinal Health: Better EPS Growth Clarity, Buying Back Shares, A Buy On Valuation
Aug 07Cardinal Health (NYSE:CAH) Shareholders Will Want The ROCE Trajectory To Continue
Aug 05An Intrinsic Calculation For Cardinal Health, Inc. (NYSE:CAH) Suggests It's 45% Undervalued
Jul 14Cardinal Health: Not A Long-Term Investment
May 24The Return Trends At Cardinal Health (NYSE:CAH) Look Promising
Apr 17Cardinal Health, Inc.'s (NYSE:CAH) Intrinsic Value Is Potentially 78% Above Its Share Price
Mar 30Cardinal Health: Downgrading Due To Absence Of Safety Margin (Rating Downgrade)
Feb 21Cardinal Health (NYSE:CAH) Is Due To Pay A Dividend Of $0.4957
Feb 16Cardinal Health declares $0.4957 dividend
Feb 10Cardinal Health FQ2 2023 Earnings Preview
Feb 01Cardinal Health partners with Palantir for data-driven supply chain support
Jan 26Cardinal Health Is A Tempting Healthcare Income Play
Dec 28Cardinal Health (NYSE:CAH) Will Pay A Dividend Of $0.4957
Dec 20Aaron Alt is the new finance chief at Cardinal health
Dec 19Is There An Opportunity With Cardinal Health, Inc.'s (NYSE:CAH) 44% Undervaluation?
Dec 14Cardinal Health (NYSE:CAH) Is Paying Out A Dividend Of $0.4957
Nov 16Cardinal Health: Investable In Potential Pullback Despite Weak Medical Segment
Nov 14Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$1b |
| Jun 30 2024 | US$26m | US$1m | US$852m |
| Mar 31 2024 | n/a | n/a | US$604m |
| Dec 31 2023 | n/a | n/a | US$691m |
| Sep 30 2023 | n/a | n/a | US$208m |
| Jun 30 2023 | US$19m | US$1m | US$330m |
| Mar 31 2023 | n/a | n/a | US$463m |
| Dec 31 2022 | n/a | n/a | -US$1b |
| Sep 30 2022 | n/a | n/a | -US$1b |
| Jun 30 2022 | US$4m | US$729k | -US$938m |
| Mar 31 2022 | n/a | n/a | -US$955m |
| Dec 31 2021 | n/a | n/a | US$555m |
| Sep 30 2021 | n/a | n/a | US$1b |
| Jun 30 2021 | US$4m | US$700k | US$611m |
| Mar 31 2021 | n/a | n/a | US$1b |
| Dec 31 2020 | n/a | n/a | US$1b |
| Sep 30 2020 | n/a | n/a | US$973m |
| Jun 30 2020 | US$4m | US$124k | -US$4b |
Compensatie versus markt: De totale vergoeding ($USD 25.65M ) Jason } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.74M ).
Compensatie versus inkomsten: De vergoeding van Jason is het afgelopen jaar met meer dan 20% gestegen.
CEO
Jason Hollar (51 yo)
2.2yrs
Tenure
US$25,650,709
Compensatie
Mr. Jason M. Hollar has been Chief Executive Officer of Cardinal Health, Inc. since September 01, 2022. He serves as Director at Cardinal Health, Inc. from August 11, 2022 and had been Chief Financial Offi...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 2.2yrs | US$25.65m | 0.0075% $ 2.2m | |
| Chief Financial Officer | 1.8yrs | US$6.84m | 0.0013% $ 360.8k | |
| Chief Legal & Compliance Officer | 5.7yrs | US$4.66m | 0.011% $ 3.1m | |
| Chief Executive Officer of Medical Segment | 5.3yrs | US$7.34m | 0% $ 0 | |
| Chief Executive Officer of Pharmaceutical & Specialty Solutions Segment | 2.2yrs | US$5.09m | 0.0083% $ 2.4m | |
| Senior VP & Chief Accounting Officer | 2.2yrs | geen gegevens | 0.0036% $ 1.0m | |
| Executive VP | 2.3yrs | geen gegevens | 0.0080% $ 2.3m | |
| Vice President of Investor Relations | no data | geen gegevens | geen gegevens | |
| Chief Human Resources Officer | 6.1yrs | geen gegevens | 0.011% $ 3.3m | |
| Executive Vice President of Biopharma Solutions & Strategic Sourcing | no data | geen gegevens | geen gegevens | |
| Senior Vice President | 1.8yrs | US$1.26m | 0.0020% $ 584.2k | |
| President of Global Products & Supply Chain | 3.7yrs | geen gegevens | geen gegevens |
2.2yrs
Gemiddelde duur
53yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van CAH wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.2 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | US$25.65m | 0.0075% $ 2.2m | |
| Independent Non-Executive Chairman | 17.3yrs | US$570.10k | 0% $ 0 | |
| Independent Director | 2.2yrs | US$318.09k | 0% $ 0 | |
| Independent Director | 11.2yrs | US$338.09k | 0.0045% $ 1.3m | |
| Independent Director | 4.3yrs | US$320.09k | 0% $ 0 | |
| Independent Director | 4.2yrs | US$338.09k | 0.0017% $ 481.1k | |
| Independent Director | 9.2yrs | US$330.61k | 0% $ 0 | |
| Independent Director | 6.8yrs | US$345.09k | 0% $ 0 | |
| Independent Director | less than a year | US$182.66k | 0% $ 0 | |
| Independent Director | 2.2yrs | US$318.09k | 0.0022% $ 627.2k |
4.3yrs
Gemiddelde duur
62yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van CAH wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).